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What does STOP-2 tell us about management of hypertension?
Sir—Lennart Hansson and colleagues
(Nov 20, p 1751),1 reporting the
Swedish Trial of Old Patients with
Hypertension (STOP-2), state that
“old and new antihypertensive drugs
were similar in prevention of
cardiovascular disease” and that
“older and newer antihypertensive
drugs are equally useful”. Since
STOP-2 was not designed to compare
individual drugs, some important
differences may have been concealed.
At the time of the study’s design and
preparation, -blockers as part of a
conventional strategy could have been
considered adequate. However, the
only trial to have permitted direct
comparison of a -blocker with a
diuretic2 and a reanalysis of older trials
according to the primary treatment
strategy in the active group3 have
demonstrated the superiority of low-
dose diuretics over -blockers in
preventing coronary heart disease.
The controls in STOP-2 received
one of three -blockers or a diuretic as
the first option, but we are not told
how many patients were initially
treated with one of them. Moreover,
pindolol, a drug implicated in
coronary risk4 and not merely the
absence of a protective effect, was one
of the -blockers used.
Diuretics were in bad company in
this trial, and the physicians should
wait for the results of trials designed to
compare drugs and not strategies
before concluding that ability to lower
blood pressure is sufficient to ascribe
the property “antihypertensive” to any
drug.
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Sir—STOP-21 was randomised but
both patients and doctors were aware
of the treatment administered.2
Information on adverse events was
collected by asking patients whether or
not new symptoms had occurred since
their last visit. This approach probably
invalidates the assessment of adverse
events presented in table 4.1 The 25%
ankle oedema in the calcium-
antagonist group and the 30% cough
in the angiotensin-converting enzyme
(ACE) inhibitor group, both much
higher than frequencies in blinded
studies,4 exemplify how expectation of
investigators and selective reporting by
patients may colour the outcome.
More importantly, the open design
may have biased the reported
incidences of non-fatal events, the
diagnosis of which rests on symptoms
or clinical signs open to interpretation,
such as congestive heart failure or
non-Q-wave infarction. The design2
does require all events to be
ascertained by a blinded committee,
but that does not rule out the
possibility that prior knowledge of the
treatment allocation results in selective
overreporting or underreporting of
events, especially in an era in which
calcium antagonists have been
subjected to controversy4 while ACE
inhibitors were proved to be of benefit
in patients with overt heart failure.
Another obstacle to interpreting
STOP-2 is the combination of
randomised treatment with second-line
antihypertensive drugs. A large
proportion of the patients allocated to
the newer drugs also received or
crossed over to conventional treatment,
because -blockers were associated
with calcium antagonists and thiazides
with ACE inhibitors. At the last visit,
46% of patients were on more than one
antihypertensive drug. Figure 5
contrasts ACE inhibitors partly
combined with diuretics, with calcium
antagonists partly combined with
-blockers—not simply ACE inhibitors
with calcium antagonists, as the legend
suggests. Moreover, only 61–66% of
patients were still taking their
randomised treatment at the last visit,
which may have further obscured true
differences beween first-line drugs.
The research question which
STOP-2 set out to resolve will remain
unsettled until the results of properly
designed double-blind trials such as
ALLHAT5 become available.
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Sir—STOP-21 was designed to detect
a 25% difference in cardiovascular
mortality between patient groups
receiving conventional or newer
antihypertensive drugs. The study was
reported as negative but we do not
believe it is possible to conclude that
there was a similar effect for the two
treatments on the primary combined
endpoint, fatal cardiovascular events.
